-In 481 patients presenting with a first flare and confirming MRI, but no definitive diagnosis.
In the interim analysis, the proportion of patients developing clinically definite multiple sclerosis (re: a second flare) was 43 percent in the placebo group compared with 25 percent in the Copaxone group, Teva said.
For those that received a clinical diagnosis of MS- the second attack was delayed to 722 days, vs. the 2nd attack average of 366 days in the placebo group-
http://www.reuters.com/article/health-S ... 03?sp=true
My husband was prescribed Copaxone after his first attack in March 2007. We're coming up on a year with no progression and no second attack.